- Conditions
- Parkinson's Disease
- Interventions
- CVN424 150 mg, Placebo
- Drug
- Lead sponsor
- Cerevance Beta, Inc.
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced May 22, 2026, 1:39 AM EDT